SCHEMBL16201380

SCHEMBL16201380

CCCN(C)Cc1n[nH]cc1-c1ccc(Cl)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 5/20 0.36
RPA1 P27694 1/20 0.34
AGTR1 P30556 2/20 0.33
AGTR2 P50052 2/20 0.33
STK4 Q13043 1/20 0.33
STK3 Q13188 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
POLB P06746 1/20 0.33
KMT2A Q03164 1/20 0.33
DRD2 P14416 1/20 0.32
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
KDM4E B2RXH2 1/20 0.32
TSHR P16473 1/20 0.32
CXCR3 P49682 2/20 0.32
SLC6A9 P48067 1/20 0.32
LMNA P02545 1/20 0.31
GFER P55789 1/20 0.31
APOBEC3G Q9HC16 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16201193 0.88 CARM1 (0.43) RPA1PRMT3CARM1PRMT6PRMT1
SCHEMBL16201371 0.86 NPSR1 (0.39) AGTR1AGTR2NPC1PRMT3CARM1
SCHEMBL16201340 0.86 TDO2 (0.33) AGTR1AGTR2DRD2HTR2AHTR2C
SCHEMBL16201358 0.83 PRMT6 (0.39) DRD2PRMT3CARM1PRMT6PRMT1
SCHEMBL16201349 0.83 HRH3 (0.43) CRHR1DRD2HTR2AHTR2CTSHR
SCHEMBL16201444 0.82 LTA4H (0.41) AGTR1AGTR2TSHRLMNA
SCHEMBL16201372 0.82 SPHK1 (0.33) AGTR1AGTR2KDM4E
SCHEMBL16201425 0.82 AGTR1 (0.35) AGTR1AGTR2MEN1POLBKMT2A
SCHEMBL16201364 0.81 PRMT6 (0.44) PRMT6PRMT1
SCHEMBL16201384 0.81 PRMT3 (0.40) CRHR1AGTR1AGTR2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9346761-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2016-05-24 US disclosed
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 CRHR1 3768/4885RPA1 1374/4885AGTR1 1953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.